Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors

April 21 (Reuters) - Zai Lab Ltd 9688.HK:

ZAI LAB ANNOUNCES ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR REPOTRECTINIB FOR PATIENTS WITH NTRK-POSITIVE SOLID TUMORS

Source text: ID:nBw75fn4wa

Further company coverage: 9688.HK

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news